Investor Presentaiton
Investor presentation
ADA 2019
Slide 18
In Dual VIII, 66% of people on glargine U100 required
treatment intensification compared to 37% on XultophyⓇ
Trial design Dual VIII - durability
"need for treatment intensification"
Duration 104 weeks
Time to need for treatment intensification*
glargine U100
Probability of need for
treatment intensification (%)
70
IDegLira
66.2% patients required
treatment intensification
Randomised:
1,012
patients
K.
IDegLira QD + OAD(s)
K
60
50
40
Insulin glargine QD + OAD(s)
30
26 weeks
Continued trial drug period
0-78 weeks
↑
20
37.4% patients required
treatment intensification
End of trial
10
"get to
target"
"durability"
0
12
26
38
52
64
78
90
104
Weeks
Trial objective
To compare long-term glycaemic control of IDegLira vs. insulin
glargine U100 in insulin naïve subjects with type 2 diabetes
inadequately controlled on OAD(s)¹
1 According to the ADA definition of HbA1c > 7%; *HbA1c ≥7% at 2 consecutive visits. Full analysis set. Treatment policy strategy. Patients discontinuing treatment contribute to analyses as
needing treatment intensification from time of discontinuation. IDegLira/Xultophy®: insulin degludec/liraglutide; Glargine U100: insulin glargine U100; n: number of patients; OAD: oral anti-
diabetes drug; QD: once-daily
novo nordiskView entire presentation